Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.
about
Local treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaTOral fluoropyrimidines among the new drugs for patients with metastatic breast cancerClinically relevant genetic variations in drug metabolizing enzymes.Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.Systems pharmacology assessment of the 5-fluorouracil pathway.Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic methodDihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study.Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityTherapeutic drug monitoring of 5-fluorouracil.An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges.Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer
P2860
Q28273580-EB70537B-A3ED-4BC7-A8F6-F02EB1B07B58Q28366029-61A8D023-D000-41B3-AE55-703D65E84F27Q35032378-4E57D9A1-7D7D-4D5B-85A0-3139C3BF391EQ35046159-05ABE25D-CB37-4862-97FE-5F507C92E127Q35072321-EF784FA6-CD79-478B-A7B2-5A32154D0192Q35811012-75DAB876-0F2F-45CD-872B-2CFC16FF15BAQ36117656-16238CBC-4B86-4322-9B37-EB1CDCEF597EQ36515540-4CBDB9E9-81F5-48B0-8E30-B14287080015Q36623852-7D47D63B-BA2D-4D09-9751-7D37A83FC26EQ36927562-BE6F0956-37B8-4F5D-B96B-27B13F4BAF1AQ37119507-DABE8A21-FFC5-4038-B923-132A86FC59E0Q37214290-D45F593A-5A02-473B-9632-3DA03C064D01Q37290672-A4534401-C8E0-4179-82F8-6DE6B37A7048Q38842633-1B93FAD7-9D94-4628-BB13-AE8F8407A347Q41881771-0533AA7F-26E4-4D5E-944F-757C1F5D965AQ55668963-55FB4536-87B3-4BB5-A784-8D4988DACDE2Q57106074-A2493864-96AC-46D8-911A-3F83C323BE3F
P2860
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Decreased dihydropyrimidine de ...... uorouracil-based chemotherapy.
@en
Decreased dihydropyrimidine de ...... uorouracil-based chemotherapy.
@nl
type
label
Decreased dihydropyrimidine de ...... uorouracil-based chemotherapy.
@en
Decreased dihydropyrimidine de ...... uorouracil-based chemotherapy.
@nl
prefLabel
Decreased dihydropyrimidine de ...... uorouracil-based chemotherapy.
@en
Decreased dihydropyrimidine de ...... uorouracil-based chemotherapy.
@nl
P2093
P1476
Decreased dihydropyrimidine de ...... luorouracil-based chemotherapy
@en
P2093
P304
P407
P577
1998-02-01T00:00:00Z